tradingkey.logo
tradingkey.logo
Suchen

Nexalin Technology Inc

NXL
Zur Watchlist hinzufügen
0.343USD
+0.003+0.74%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
7.05MMarktkapitalisierung
VerlustKGV TTM

Nexalin Technology Inc

0.343
+0.003+0.74%

mehr Informationen über Nexalin Technology Inc Unternehmen

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc Informationen

BörsenkürzelNXL
Name des UnternehmensNexalin Technology Inc
IPO-datumSep 16, 2022
CEOWhite (Mark)
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeSep 16
Addresse1776 Yorktown
StadtHOUSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl77056
Telefon18322600222
Websitehttps://nexalin.com
BörsenkürzelNXL
IPO-datumSep 16, 2022
CEOWhite (Mark)

Führungskräfte von Nexalin Technology Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.21M
-27.03%
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
192.25K
+3.38%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
119.59K
+30.49%
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Device Sales
136.00K
45.09%
Equipment
89.04K
29.52%
Licensing Fee
49.11K
16.28%
Other
27.49K
9.11%
Nach RegionUSD
Name
Umsatz
Anteil
International Sales
190.30K
63.09%
U.S. Sales
111.35K
36.91%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Device Sales
136.00K
45.09%
Equipment
89.04K
29.52%
Licensing Fee
49.11K
16.28%
Other
27.49K
9.11%

Aktionärsstatistik

Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Elson (Marilyn)
5.87%
Peak6 Capital Management LLC
2.32%
Hu (Benjamin)
1.83%
White (Mark)
1.50%
Owens (David)
0.93%
Andere
87.54%
Aktionäre
Aktionäre
Anteil
Elson (Marilyn)
5.87%
Peak6 Capital Management LLC
2.32%
Hu (Benjamin)
1.83%
White (Mark)
1.50%
Owens (David)
0.93%
Andere
87.54%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
11.23%
Investment Advisor
3.81%
Investment Advisor/Hedge Fund
1.00%
Hedge Fund
0.89%
Research Firm
0.36%
Andere
82.70%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
43
1.43M
6.94%
+524.95K
2025Q4
38
722.74K
3.87%
-783.30K
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Elson (Marilyn)
1.54M
7.46%
--
--
Jun 04, 2025
Peak6 Capital Management LLC
476.51K
2.32%
+476.51K
--
Dec 31, 2025
Hu (Benjamin)
377.10K
1.83%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.5%
--
--
Jun 04, 2025
Owens (David)
185.75K
0.9%
+36.46K
+24.42%
Sep 29, 2025
Geode Capital Management, L.L.C.
150.27K
0.73%
+28.45K
+23.36%
Dec 31, 2025
Renaissance Technologies LLC
122.10K
0.59%
+66.40K
+119.21%
Dec 31, 2025
Kazden (Alan)
83.13K
0.4%
--
--
Jun 04, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI